Oncology Deal Benchmarks
The most active therapeutic area for biopharma deals. Benchmark licensing terms, ADC partnerships, immuno-oncology collaborations, and M&A across solid tumors and hematologic malignancies. Benchmarks derived from 1,229 verified transactions.
1,229
Total Deals
$438M
Avg Upfront
7
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
449
license
169
acquisition
248
collaboration
87
option
42
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
SciBrunch Therapeutics → Merck SPR2015 | license | $400M | $2.1B | Sep 2026 |
Alphamab Oncology → Pathos AI JSKN016 | license | $125M | $2.2B | Sep 2026 |
Amberstone Biosciences, Inc. → Shanghai Henlius Biotech, Inc. | collaboration | $4M | $888M | Sep 2026 |
ITM Isotope Technologies Munich → Telix ITM-11 (177Lu-edotreotide) | acquisition | $1.6B | $2.4B | Sep 2026 |
Hutchmed → GSK HMPL-A830 | license | $110M | $1.4B | Sep 2026 |
Innate Pharma → Swedish Orphan Biovitrum (Sobi) Lacutamab | option | $75M | $580M | Sep 2026 |
Hutchmed → GSK HMPL-A830 | license | $110M | $1.3B | Sep 2026 |
ITM Isotope Technologies Munich SE → Telix Pharmaceuticals ITM-11 (and ITM radiopharmaceutical portfolio) | acquisition | $1.6B | $2.4B | Sep 2026 |
Convergent Genomics → Veracyte UroAmp | acquisition | $150M | $180M | Sep 2026 |
HUTCHMED → GSK HMPL-A830 | license | $110M | $1.3B | Sep 2026 |
Benchmark Your Oncology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 1,229 verified oncology transactions.
Oncology Deal Benchmarking FAQ
What are typical upfront payments in oncology licensing deals?
Oncology licensing upfronts vary widely by modality and stage. ADC and bispecific deals command premium upfronts ($50M-$300M+ for clinical-stage assets), while small molecule oncology deals typically range $20M-$100M. Solidus benchmarks are derived from verified SEC filings and press releases across all oncology sub-segments.
How do oncology deal structures compare to other therapeutic areas?
Oncology consistently leads in total deal volume and competition for assets. Deals tend to feature higher milestone-to-upfront ratios, reflecting clinical risk in late-stage trials. Royalty rates for marketed oncology products typically range 15-25%, above the cross-TA median of 10-18%.
What oncology modalities are driving the most deal activity in 2026?
ADCs (antibody-drug conjugates), bispecific antibodies, and radiopharmaceuticals are the most active oncology modalities in 2026. ADC deals have seen upfront payments increase 40%+ since 2023, driven by competition for next-gen payloads and novel targets beyond HER2 and Trop2.